|
|
Volumn 324, Issue 7350, 2002, Pages 1389-1391
|
|
Clinical endpoints in trials of drugs for cancer: Time for a rethink?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
CERIVASTATIN;
CISAPRIDE;
GASTROINTESTINAL AGENT;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
TETRAHYDROLIPSTATIN;
CANCER CHEMOTHERAPY;
CHRONIC MYELOID LEUKEMIA;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG RESEARCH;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPERTENSION;
LEUKOCYTE COUNT;
OBESITY;
PHILADELPHIA 1 CHROMOSOME;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REFLUX ESOPHAGITIS;
SHORT SURVEY;
VIRUS HEPATITIS;
VIRUS LOAD;
|
|
EID: 0037042676
PISSN: 09598146
EISSN: None
Source Type: Journal
DOI: 10.1136/bmj.324.7350.1389 Document Type: Short Survey |
|
Times cited : (13)
|
|
References (18)
|
